• Pyxis Oncology launched a registered public offering of common stock or pre-funded warrants, each paired with a common warrant.
• Common warrants become exercisable only after stockholder approval of a charter amendment increasing authorized common shares.
• Warrants expire on the earlier of five years from the charter amendment effective date or 30 days after MICVO overall survival data disclosure.
• Proceeds earmarked to advance MICVO, including the planned Phase 3 Headliner trial in 2L+ R/M HNSCC, plus working capital.
• Leerink Partners, Guggenheim Securities, Wells Fargo Securities named joint bookrunning managers; deal terms remain subject to market conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609291624PRIMZONEFULLFEED9836351) on September 29, 2026, and is solely responsible for the information contained therein.